Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors
Alexandra E. Gould*†, Ruth Adams†, Sharmila Adhikari†, Kathleen Aertgeerts‡, Roushan Afroze†, Christopher Blackburn†, Emily F. Calderwood†, Ryan Chau†, Jouhara Chouitar†, Matthew O. Duffey†, Dylan B. England†, Cheryl Farrer†, Nancy Forsyth†, Khristofer Garcia†, Jeffery Gaulin†, Paul D. Greenspan†, Ribo Guo†, Sean J. Harrison†, Shih-Chung Huang†, Natalia Iartchouk†, Dave Janowick†, Mi-Sook Kim†, Bheemashankar Kulkarni†, Steven P. Langston†, Jane X. Liu†, Li-Ting Ma†, Saurabh Menon†, Hirotake Mizutani†, Erin Paske†, Christelle C. Renou†, Mansoureh Rezaei†, R. Scott Rowland†, Michael D. Sintchak†, Michael D. Smith†, Stephen G. Stroud†, Ming Tregay†, Yuan Tian†, Ole P. Veiby†, Tricia J. Vos†, Stepan Vyskocil†, Juliet Williams†, Tianlin Xu†, Johnny J. Yang†, Jason Yano‡, Hongbo Zeng†, Dong Mei Zhang†, Qin Zhang†, and Katherine M. Galvin†
J. Med. Chem., 2011, 54 (6), pp 1836–1846
- DOI:
http://dx.doi.org/10.1021/jm101479y
